Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596645 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study of Colitis, Ulcerative, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT03596645 is a Phase 3 study of Colitis, Ulcerative that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 84 participants, below the 403-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03596645, a Phase 3 study of Colitis, Ulcerative, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC). In addition, the safety profile of golimumab, in pediatric participants with moderately to severely active UC will be assessed.
Conditions Studied
Interventions
- DRUG Infliximab
- DRUG Golimumab
Study Locations (20)
Other
- Universitair Kinderziekenhuis Koningin Fabiola - Brussels
- Cliniques Universitaires Saint Luc - Brussels
- UZ Brussel - Jette
- MK Blumenau Pesquisa Clínica - Blumenau
- Hospital Pequeno Principe - Curitiba
- Irmandade Santa Casa de Misericordia de Porto Alegre - Porto Alegre
- BR Trials - São Paulo
- Hopital Pellegrin CHU Bordeaux - Bordeaux
Texas
- Children's Medical Center of Dallas - Dallas
- Cook Childrens Medical Center - Fort Worth
- DHAT Research Institute - Garland
Colorado
- Children's Hospital Colorado and University of Colorado - Aurora
- Rocky Mountain Pediatric Gastroenterology - Lone Tree
California
- University of California San Francisco - San Francisco
Connecticut
- Connecticut Children's Medical Center - Hartford
Delaware
- Nemours DuPont Hospital for Children - Wilmington
Georgia
- Children's Center for Digestive Health Care - Atlanta
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2027-02-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596645
The ClinicalTrials.gov registry entry for NCT03596645 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 403-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (79% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colitis, Ulcerative appearing as the primary indexed condition, and to 2 interventions - of which Infliximab is the first listed.
NCT03596645 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT03596645 about?
NCT03596645 is a clinical study titled "A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis". The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC). In addition, the safety profile of golimumab, in pediatric participants with moderately t...
What is the current status of trial NCT03596645?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2018-10-29. Estimated completion is 2027-02-20.
What conditions does trial NCT03596645 study?
This clinical trial studies the following conditions: Colitis, Ulcerative.
What interventions are being tested in trial NCT03596645?
The interventions under investigation include: Infliximab (DRUG), Golimumab (DRUG).
Who is sponsoring clinical trial NCT03596645?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03596645 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Delaware, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colitis, Ulcerative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.